Bleeding diathesis in patients with mast cell activation disease

• 

^* These authors contributed equally to the study

• References

• 1 Campbell Jr, EW, Hector D, Gossain V. Heparin activity in systemic mastocytosis. Ann Intern Med 1979; 90: 940-941.
• 2 Adler SN, Klein RA, Lyon DT. Bleeding after liver biopsy in a patient with systemic mastocytosis and malabsorption. J Clin Gastroenterol 1985; 7: 350-353.
• 3 Horan RF, Austen KF. Systemic mastocytosis: restrospective review of a decade´s clinical experience at the Brigham and Women´s Hospital. J Invest Dermatol 1991; 96 (Suppl.) 5S-14S.
• 4 Parker RI. Hematologic aspects of systemic mastocytosis. Mast Cell Disorders 2000; 14: 557-568.
• 5 Puretic S, Milavec D. Clinical varieties of mastocytoses. Acta Med Croatica 2001; 55: 61-66.
• 6 Koenig M, Morel J, Reynaud J. et al. An unusual cause of spontaneous bleeding in the intensive care unit - mastocytosis: a case report. Cases J 2008; 1: 100
• 7 Sucker C, Mansmann G, Steiner S. et al. Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost 2008; 14: 360-364.
• 8 Steiner DR, Gonzalez NC, Wood JG. Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 2003; 94: 325-334.
• 9 Stevens RL, Fox CC, Lichtenstein LM. et al. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA 1988; 85: 2284-2287.
• 10 Sillaber C, Baghestanian M, Bevec D. et al. The mast cell as site of tissue type plasminogen activator production and fibrinolysis. J Immunol 1999; 62: 1032-1041.
• 11 Strbian D, Karjalainen-Lindsberg ML, Kovanen PT. et al. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007; 116: 411-418.
• 12 Hertfelder HJ, Popov-Cenic S. Short-time centrifugation at high centrifugal forces in plasma preparation for tPA activity determination. Thromb Res 1990; 59: 417-420.
• 13 Molderings GJ, Meis K, Kolck UW. et al. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010; 62: 721-727.